Screening-based translation of public research encounters painful problems

ACS Medicinal Chemistry Letters

Volumn 6, Issue 3, 2015, Pages 229-234

  Baell, Jonathan B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; BENZIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; CATECHOL DERIVATIVE; CATIONIC AMPHIPHILIC DRUG; CHEMICAL COMPOUND; ELTROMBOPAG; ENZYME INHIBITOR; IMINOBENZIMIDAZOLE; LIGAND; NAVITOCLAX; NEUROLEPTIC AGENT; NEW DRUG; PAN ASSAY INTERFERENCE COMPOUND; PROTEIN; QUINOLONE DERIVATIVE; QUINONE DERIVATIVE; TRYPANOTHIONE REDUCTASE; TRYPANOTHIONE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; VEMURAFENIB;

CHEMICAL STRUCTURE; COMPUTER MODEL; DRUG APPROVAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEDICAL LITERATURE; MEDICINAL CHEMISTRY; MOLECULE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SEARCH ENGINE; STRUCTURE ACTIVITY RELATION;

EID: 84924708699     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00032     Document Type: Review

References (37)

1. Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic, D. A.; Garyantes, T.; Green, D. V. S.; Hertzberg, R. P.; Janzen, W. P.; Paslay, J. W.; Schopfer, U.; Sittampalam, G. S. Impact of highthroughput screening in biomedical research Nat. Rev. Drug Discovery 2011, 10, 188-195
2. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds [PAINS] from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740
3. Baell, J. B. Observations on Screening-Based Research and Some Concerning Trends in the Literature Future Med. Chem. 2010, 2, 1529-1546
4. Baell, J. B.; Ferrins, L.; Falk, H.; Nikolakopoulos, G. PAINS: Relevance to Tool Compound Discovery and Fragment-Based Screening Aust. J. Chem. 2013, 66, 1483-1494
5. Baell, J.; Walters, M. A. Chemical con artists foil drug discovery Nature 2014, 513, 481-483
6. PAINS Go Mainstream. http://pipeline.corante.com/archives/2014/09/26/pains-go-mainstream.php.
7. Nicolaes, G. A. F.; Kulharia, M.; Voorberg, J.; Kaijen, P. H.; Wroblewska, A.; Wielders, S.; Schrijver, R.; Sperandio, O.; Villoutreix, B. O. Rational design of small molecules targeting the C2 domain of coagulation factor VIII Blood 2014, 123, 113-120
8. Evelyn, C. R.; Duan, X.; Biesiada, J.; Seibel, W. L.; Meller, J.; Zheng, Y. Rational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1 Chem. Biol. 2014, 21, 1-11
9. Wang, G.; Wang, X.; Yu, H.; Wei, S.; Williams, N.; Holmes, D. L.; Halfmann, R.; Naidoo, J.; Wang, L.; Li, L.; Chen, S.; Harran, P.; Lei, X.; Wang, X. Small-molecule activation of the TRAIL receptor DR 5 in human cancer cells Nat. Chem. Biol. 2013, 9, 84-89
10. Chen, F.; Liu, J.; Huang, M.; Hu, M.; Su, Y.; Zhang, X.-K. Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site ACS Med. Chem. Lett. 2014, 5, 736-741
11. Xin, M.; Li, R.; Xie, M.; Park, D.; Owonikoko, T. K.; Sica, G. L.; Corsino, P. E.; Zhou, J.; Ding, C.; White, M. A.; Magis, A. T.; Ramalingam, S. S.; Curran, W. J.; Khuri, F. R.; Deng, X. Small molecule Bax agonists for cancer therapy. Nat. Commun. 2014, 5, 4935
12. Lessene, G.; Czabotar, P.; Sleebs, B. E.; Zobel, K.; Lowes, K. L.; Adams, J. M.; Baell, J. B.; Colman, P. M.; Deshayes, K.; Fairbrother, W. J.; Flygare, J. A.; Gibbons, P.; Kersten, W. J. A.; Kulasegaram, S.; Moss, R. M.; Parisot, J. P.; Smith, B. J.; Street, I. P.; Yang, H.; Huang, D. C. S.; Watson, K. G. Structure-guided design of a selective BCL-XL inhibitor Nat. Chem. Biol. 2013, 9, 390-397
13. Sleebs, B.; Kersten, W.; Kulasegaram, S.; Nikolakopoulos, G.; Hatzis, E.; Moss, R.; Parisot, J.; Yang, H.; Czabotar, P.; Fairlie, W.; Lee, E.; Adams, J.; Chen, L.; van Delft, M.; Lowes, K.; Wei, A.; Huang, D.; Colman, P.; Street, I.; Baell, J.; Watson, K.; Lessene, G. Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL J. Med. Chem. 2013, 56, 5515-5540
14. Koehler, M. F. T.; Bergeron, P.; Choo, E. F.; Lau, K.; Ndubaku, C.; Dudley, D.; Sleebs, B. E.; Rye, C. S.; Nikolakopoulos, G.; Bui, C.; Kulasegaram, S.; Kersten, W. J. A.; Smith, B. J.; Czabotar, P. E.; Colman, P. M.; Huang, D. C. S.; Baell, J. B.; Watson, K. G.; Hasvold, L.; Tao, Z.-F.; Wang, L.; Souers, A. J.; Elmore, S. W.; Flygare, J. A.; Fairbrother, W. J.; Lessene, G. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL ACS Med. Chem. Lett. 2014, 5, 662-667
15. Zhang, W.; DeRyckere, D.; Hunter, D.; Liu, J.; Stashko, M. A.; Minson, K. A.; Cummings, C. T.; Lee, M.; Glaros, T. G.; Newton, D. L.; Sather, S.; Zhang, D.; Kireev, D.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor J. Med. Chem. 2014, 57, 7031-7041
16. Baell, J. B. Broad coverage of commercially available lead-like screening space with fewer than 350,000 Compounds J. Chem. Inf. Model. 2013, 53, 39-55
17. Belema, M.; Meanwell, N. A. Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect J. Med. Chem. 2014, 57, 5057-5071
18. Diaz, E.; Machutta, C. A.; Chen, S.; Jiang, Y.; Nixon, C.; Hofmann, G.; Key, D.; Sweitzer, S.; Patel, M.; Wu, Z.; Creasy, C. L.; Kruger, R. G.; LaFrance, L.; Verma, S. K.; Pappalardi, M. B.; Le, B.; Van Aller, G. S.; McCabe, M. T.; Tummino, P. J.; Pope, A. J.; Thrall, S. H.; Schwarz, B.; Brandt, M. Development and validation of reagents and assays for EZH2 peptide and nucleosome highthroughput screens J. Biomol. Screening 2012, 17, 1279-1292
19. Aube, J. Drug repurposing and the medicinal chemist ACS Med. Chem. Lett. 2012, 3, 442-444
20. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs J. Med. Chem. 2003, 46, 4477-86
21. Anderson, N.; Borlak, J. Drug-induced phospholipidosis FEBS Lett. 2006, 580, 5533-5540
22. Kazmi, F.; Hensley, T.; Pope, C.; Funk, R. S.; Loewen, G. J.; Buckley, D. B.; Parkinson, A. Lysosomal Sequestration (Trapping) of Lipophilic Amine (Cationic Amphiphilic) Drugs in Immortalized Human Hepatocytes (Fa2N-4 Cells) Drug Metab. Dispos. 2013, 41, 897-905
23. Gehring, G.; Rohrmann, K.; Atenchong, N.; Mittler, E.; Becker, S.; Dahlmann, F.; Pohlmann, S.; Vondran, F. W. R.; David, S.; Manns, M. P.; Ciesek, S.; von Hahn, T. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry J. Antimicrob. Chemother. 2014, 69, 2123-2131
24. Carver, J.; Dexheimer, T. S.; Hsu, D.; Weng, M.-T.; Smith, J. L.; Guha, R.; Jadhav, A.; Simeonov, A.; Luo, J. A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein PLoS One 2014, 9, e103836
25. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 2007, 6, 29-40
26. Bista, M.; Smithson, D.; Pecak, A.; Salinas, G.; Pustelny, K.; Min, J.; Pirog, A.; Finch, K.; Zdzalik, M.; Waddell, B.; Wladyka, B.; Kedracka-Krok, S.; Dyer, M. A.; Dubin, G.; Guy, R. K. P. On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53 PLoS One 2012, 7, e37518
27. Guest Blog: Dr. Jonathan Baell, Medicinal Chemistry Group Leader, CRC for Cancer Therapeutics at WEHI. https://www.collaborativedrug.com/buzz/2010/03/08/guest-blog-dr-jonathan-baell/.
28. Lagorce, D.; Maupetit, J.; Baell, J.; Sperandio, O.; Tuffery, P.; Miteva, M. A.; Galons, H.; Villoutreix, B. O. The FAF-Drugs2 server: a multistep engine to prepare electronic compound collections Bioinformatics 2011, 27, 2018-2020
29. Saubern, S.; Guha, R.; Baell, J. B. KNIME workflow to assess PAINS filters in SMARTS format. Comparison of RDKit and Indigo cheminformatics libraries Mol. Informatics 2011, 30, 847-850
30. Ringel, M.; Tollman, P.; Hersch, G.; Schulze, U. Does size matter in R&D productivity? If not, what does? Nature Rev Drug Discovery 2013, 12, 901-902
31. Practical Fragments. PAINS Shaming, part deux. http://practicalfragments.blogspot.com.au/2014/12/pains-shaming-part-deux.html.
32. More Odd Compounds. Comments. http://pipeline.corante.com/archives/2015/01/07/more-odd-compounds.php#comments.
33. Are Your Compounds Ugly? Do You Know? http://pipeline.corante.com/archives/2014/09/04/are-your-compounds-ugly-do-you-know.php.
34. Deng, H.; Fang, Y. The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists Pharmaceuticals 2013, 6, 500-509
35. Antolin, A. A.; Mestres, J. Distant polypharmacology among MLP chemical probes ACS Chem. Biol. 2014, 10.1021/cb500393m
36. Tsukamoto, T. Tough times for medicinal chemists: are we to blame? ACS Med. Chem. Lett. 2013, 4, 369-370
37. Eder, J.; Sedrani, R.; Wiesmann, C. The discovery of first-in-class drugs: origins and evolution Nature Rev. Drug Discov. 2014, 13, 577-587